Loading...
01/11 03:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlighted strong financial performance, including a 217% increase in prescription transaction revenue and a positive adjusted EBITDA margin. Despite potential risks like Rite Aid's bankruptcy, the impact is expected to be minimal. The share repurchase program and positive guidance on pharma solutions growth further boost sentiment. However, some concerns about pricing pressures and competition were noted. Given the company's market cap, these factors collectively suggest a positive stock price movement of 2% to 8% over the next two weeks.
Total Revenue $203,000,000, up 3% year-over-year. This increase is attributed to growth in prescription transaction revenue and manufacturer solutions.
Prescription Transaction Revenue Up 217% year-over-year. This significant growth reflects the company's strong partnerships and increased utilization of their services.
Adjusted EBITDA $69,800,000, rose 11% year-over-year, resulting in an adjusted EBITDA margin of 34.4%. This improvement is due to operational efficiencies and revenue growth.
Cash Balance $301,000,000 at the end of the quarter, with $91,700,000 of unused capacity on the revolving line of credit, resulting in total liquidity of $392,700,000.
Share Repurchase Approximately $100,000,000 deployed to repurchase 23,300,000 shares at an average price of $4.32 per share, indicating confidence in the stock's value.
Adjusted EBITDA Guidance Expected to be between $273,000,000 and $287,000,000 for the full year, representing approximately 5% to 10% growth compared to 2024.
New e-commerce solution: Launched a new integrated e-commerce solution for retail pharmacies that checks medication inventory, validates prescriptions, and allows consumers to pay on GoodRx before picking up their prescriptions.
Point of Sale Discount Programs: Expanded partnerships with pharmaceutical manufacturers to offer point of sale cash price discounts directly to consumers.
Market Positioning: GoodRx was recognized as one of Newsweek and USA Today’s 2025 most trusted brands, reinforcing its strong market position.
Pharmacy Partnerships: Strengthened partnerships with pharmacies to address customer affordability issues and enhance profitability.
Leadership Changes: Appointed new leadership including Erin Crittenden as president of Rx marketplace and Scott Pope as chief pharmacy officer to enhance operational efficiency.
Consumer Engagement: Over 12 million consumers and 750,000 healthcare professionals used GoodRx in Q1 2025, indicating strong engagement.
Strategic Focus: Focused on high-impact initiatives to deepen partnerships with pharmacies and pharmaceutical manufacturers, enhancing the overall value proposition.
Response to Rite Aid Bankruptcy: Actively engaging with pharmacy partners to ensure smooth transitions for consumers affected by Rite Aid's bankruptcy.
Regulatory and Policy Changes: Ongoing uncertainty in the macroeconomic environment driven by regulatory and policy changes could influence the business.
Rite Aid Bankruptcy: The recent bankruptcy announcement of Rite Aid poses a risk, as it may impact GoodRx's revenue, although it is forecasted to be less than 5% of total revenue for 2025.
Consumer Sentiment: Shifting consumer sentiment may affect the demand for GoodRx's services, particularly in the context of economic conditions.
Supply Chain Challenges: The company acknowledges challenges related to supply chain dynamics, particularly in the pharmacy ecosystem.
Competitive Pressures: Increased competition from other pharmacies and manufacturers may impact GoodRx's market position and pricing strategies.
Economic Factors: The overall economic climate, including consumer confidence and spending trends, could influence revenue and growth prospects.
Pricing Pressures: Some prescription pricing has increased across the platform, which has led to pressure on overall monthly active consumers.
Partnership Dynamics: The need to maintain beneficial partnerships with pharmacies and manufacturers is critical, as any disruption could affect service delivery and revenue.
Leadership Changes: GoodRx appointed Erin Crittenden as president of the Rx marketplace, Scott Pope as chief pharmacy officer, and Gary Klein as senior vice president of government affairs to strengthen the leadership team and enhance partnerships.
E-commerce Strategy: Launched a new integrated e-commerce solution for retail pharmacies to streamline workflows and improve consumer experience.
Partnerships with Pharmacies: Focused on closer partnerships with retail pharmacies to enhance profitability and improve consumer access to medications.
Integrated Savings Program (ISP): Evaluating the evolution of the ISP to provide more value, including extending offerings into non-covered medications.
Pharma Manufacturer Solutions: Continued to drive access and affordability solutions, expanding partnerships with pharmaceutical brands.
Revenue Guidance: For full year 2025, revenue is expected to be in the range of $810 million to $840 million, representing 2% to 6% growth compared to 2024.
Adjusted EBITDA Guidance: Adjusted EBITDA is expected to be between $273 million and $287 million, representing approximately 5% to 10% growth compared to 2024.
Q2 Revenue Expectations: Q2 revenue is expected to be up sequentially from $203 million reported in Q1.
Impact of Rite Aid Bankruptcy: Rite Aid is forecasted to be less than 5% of total revenue in 2025, with ongoing efforts to ensure smooth transitions for affected consumers.
Share Repurchase Program: In the first quarter, GoodRx deployed approximately $100,000,000 to repurchase 23,300,000 shares at an average price of $4.32 per share. At the end of the quarter, approximately $189,000,000 of capacity remained under the $450,000,000 share repurchase program.
The earnings call summary and Q&A indicate strong growth prospects, particularly in manufacturer solutions and strategic initiatives, despite some headwinds like Rite Aid bankruptcy. The positive sentiment is reinforced by management's optimistic guidance and strategic focus on market expansion and partnerships. The market cap suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
The earnings call presents mixed signals. Financial performance guidance shows modest growth, but there's a decline in gold subscriptions and uncertainty in consumer behavior. The Q&A reveals management's vague responses, which could concern investors. However, new product launches and strategic initiatives, like leveraging a large consumer base and cost controls, provide optimism. The market cap suggests moderate volatility, leading to a neutral prediction for stock price movement.
The earnings call highlighted strong financial performance, including a 217% increase in prescription transaction revenue and a positive adjusted EBITDA margin. Despite potential risks like Rite Aid's bankruptcy, the impact is expected to be minimal. The share repurchase program and positive guidance on pharma solutions growth further boost sentiment. However, some concerns about pricing pressures and competition were noted. Given the company's market cap, these factors collectively suggest a positive stock price movement of 2% to 8% over the next two weeks.
The earnings call summary shows solid financial performance with a 3% revenue increase and 11% EBITDA growth. The share repurchase program is a positive shareholder return strategy, and the Q&A revealed ongoing strategic partnerships and growth initiatives. Although guidance is cautious, the market strategy, including expanding partnerships and engaging healthcare professionals, is promising. The market cap of $2.8 billion suggests moderate volatility, supporting a positive prediction for stock movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
